Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Management of adverse events associated with idelalisib treatment: expert panel opinion2015 · 313 citations
2. 2Survival probabilities (the Kaplan-Meier method)1998 · 850 citations
3. 3Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines2008 · 3,808 citations
4. 4Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib2017 · 120 citations
5. 5Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group2016 · 118 citations